NewBridge to Offer Verinata's Verifi Test in Middle East, Africa | GenomeWeb

NEW YORK (GenomeWeb News) – NewBridge Pharmaceuticals today announced an agreement to offer Verinata Health's non-invasive prenatal tests in the Middle East and surrounding areas.

Under the exclusive agreement, NewBridge will offer Verinata's Verifi test in the Middle East, Africa, Turkey, and Caspian regions. Financial terms of the deal were not disclosed.

Based in Dubai, United Arab Emirates, NewBridge is a specialty therapeutics firm that commercializes pharmaceuticals, biologics, diagnostics, and medical devices in the Middle East and neighboring areas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.